2.2 Potential drug candidates in clinical trials
Remdesivir (GS-5734) is an adenosine analogue that has completed the phase III clinical trial for the treatment of Ebola virus infection. The antiviral drug remdesivir (GS-5734) is entered to the phase III clinical trials in Asian countries to assess the use of antiviral drug candidate for the potential treatment of coronavirus by Gilead Sciences. All reported potential drug candidates in clinical trials and their status are presented in Table 2. Moreover, multiple parallel attempts are in progress to develop 2019-nCoV vaccine. Currently 18 vaccine candidates are in preclinical phases and five candidates are in clinical phases (Table 3).